Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $423.61M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.79M
Average 1.82M
Returns on capital
Candel Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.5%
avg -53.2%
ROIC
-41.4%
avg -46.6%
ROA
-30.5%
avg -43.3%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -43.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Paul-Peter Tak FOCIS | President, Chief Executive Officer & Director | USD 1.03M | 66 | — | — |
Seshu Tyagarajan | Chief Technical & Development Officer | USD 613.23K | 58 | 76.86K | 0.14% |
Francesca Barone | Chief Scientific Officer | USD 497.31K | 48 | 77.36K | 0.14% |
Charles Schoch | Senior VP, CFO, Treasurer & Secretary | USD 412.03K | 41 | 232.00K | 0.42% |
Mark Sims | Chief Commercial Officer | — | — | — | — |
Theodore Jenkins | Vice President of Investor Relations & Business Development | — | — | — | — |
William Nichols Garrett | Chief Medical Officer | — | 57 | 136.50K | 0.25% |
Ileen Winick | Chief People Officer | — | — | — | — |
Susan Stewart | Chief Regulatory Officer | — | 65 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$3.00M
Sells
5
$3.55M
Net Transaction Value
−$550,707.38
Net selling
Most Active
Tak Paul Peter
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 11, 26Sep 11, 2026 | Tak Paul Peter Direct | Sell | $620.9K$620,890.58 |
| Sep 10, 26Sep 10, 2026 | Tak Paul Peter Direct | Sell | $2.5M$2,539,892.74 |
| Aug 17, 26Aug 17, 2026 | Tyagarajan Seshu Direct | Sell | $84K$84,000.00 |
| Jun 29, 26Jun 29, 2026 | Barone Francesca Direct | Sell | $235.8K$235,768.96 |
| Jun 29, 26Jun 29, 2026 | Tyagarajan Seshu Direct | Sell | $70.2K$70,151.20 |
| Feb 23, 26Feb 23, 2026 | Manning Paul B Indirect | Buy | $3M$2,999,996.10 |
Summary
Insiders reported 1 buys worth $3.00M and 5 sells worth $3.55M over the last 12 months. That adds up to net selling of $550,707.38. Tak Paul Peter was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Candel Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CADL's management, answered from reported figures.
Who manages CADL?
Candel Therapeutics, Inc. (CADL) lists 9 active executives. The top listed executive is Mark Sims, Chief Commercial Officer.
Are CADL insiders buying or selling?
Recent insider activity shows net buying of $23.28M.
Continue the stock analysis
Jump to another research area for this company.